MGNX MacroGenics, Inc.

NASDAQ
$3.74

MacroGenics, Inc. (MGNX) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.9% since its last earnings release on August 13, 2026.

MacroGenics Beat Consensus Estimates
Thursday, August 13, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.10)
Rev est $62.01M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.12

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MacroGenics, Inc.

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.